NTLA Earnings Date: Nov 5, 2026 (Estimated) — Intellia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is NTLA's next earnings date?
Intellia Therapeutics, Inc. (NTLA) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.80 on revenue of $9.7M.
How did NTLA do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Intellia Therapeutics, Inc. posted EPS of -$0.80 versus the -$0.80 estimate, a miss of 0.0%. Revenue was $7.7M against a $13.0M estimate. The stock's 1-day post-earnings move was +2.5%.
How much does NTLA stock move after earnings?
NTLA beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.5% (up or down) in the day after earnings.
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.80 | -0.80 | +0.00% | $7.7M | ❌ Miss | +2.46% | +10.21% | +15.59% |
| 2026-05-11 | Q1 2026 | -0.90 | -0.81 | +10.00% | $15.0M | ✅ Beat | +2.34% | -2.98% | -8.52% |
| 2026-02-26 | Q4 2025 | -0.97 | -0.83 | +14.43% | $23.0M | ✅ Beat | +6.41% | +2.98% | -1.34% |
| 2025-11-06 | Q3 2025 | -1.00 | -0.92 | +8.00% | $13.8M | ✅ Beat | -9.21% | -30.07% | -29.18% |
| 2025-08-07 | Q2 2025 | -1.02 | -0.98 | +3.92% | $14.2M | ✅ Beat | +0.79% | -3.25% | +6.16% |
| 2025-05-08 | Q1 2025 | -1.27 | -1.10 | +13.39% | $16.6M | ✅ Beat | +13.58% | +8.09% | +10.97% |
| 2025-02-27 | Q4 2024 | -1.32 | -1.27 | +3.79% | $12.9M | ✅ Beat | +0.56% | -13.29% | -22.22% |
| 2024-11-07 | Q3 2024 | -1.38 | -1.34 | +2.90% | $9.1M | ✅ Beat | -0.37% | +0.31% | -8.34% |
Showing last 8 quarters.